The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).
 
Changhoon Yoo
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Ipsen; MSD Oncology; SERVIER
Speakers' Bureau - Bayer; Celgene; Eisai; Ipsen; Merck Sharp & Dohme
Research Funding - AstraZeneca; Bayer; CKD pharm; SERVIER
 
Hyehyun Jeong
No Relationships to Disclose
 
Kyu-Pyo Kim
No Relationships to Disclose
 
Dae Wook Hwang
No Relationships to Disclose
 
Jae-Hoon Lee
No Relationships to Disclose
 
Ki-Hun Kim
No Relationships to Disclose
 
Deok Bok Moon
No Relationships to Disclose
 
Myung Ah Lee
No Relationships to Disclose
 
Se Jun Park
No Relationships to Disclose
 
Hong Jae Chon
No Relationships to Disclose
 
Jin-hong Park
No Relationships to Disclose
 
Ji Sung Lee
No Relationships to Disclose
 
Baek-Yeol Ryoo
No Relationships to Disclose